Published in final edited form as:

Clin Cancer Res. 2012 November 15; 18(22): 6178–6187. doi:10.1158/1078-0432.CCR-12-1876.

Establishment and Characterization of Novel Cell Lines from Sinonasal Undifferentiated Carcinoma

Yoko Takahashi¹, Michael E. Kupferman¹, Diana Bell², Tilahun Jiffar¹, June Goo Lee¹, Tong-Xin Xie¹, Ning-Wei Li^{1,3}, Mei Zhao¹, Mitchell J. Frederick¹, Alexander Gelbard⁴, Jeffrey N. Myers¹, and Ehab Y. Hanna¹

¹Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas

²Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas

³Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China

⁴Department of Otolaryngology-Head & Neck Surgery, Baylor College of Medicine, Houston, Texas

Abstract

Purpose—Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive cancer. Despite the use of multi-modality treatment, the overall prognosis remains poor. To better understand the biological features of SNUC and help develop new therapies for the disease, we established SNUC cell lines and characterized their biological behaviors.

Methods—Cell lines were established from a patient with a T4N0M0 SNUC of the right maxillary sinus who was treated with surgical resection at our center. Tumor colonies were harvested and were sequentially replated onto larger plates. Two populations were developed and labeled MDA8788-6 and MDA8788-7. These cell lines were characterized with molecular, biomarker, functional and histologic analyses.

Results—Short tandem repeat genotyping revealed that the cell line is isogenic to the parental tumor, and cytogenetic analysis identified 12 chromosomal translocations. The SNUC cell lines do not form colonies in soft agar, but are tumorigenic and non-metastatic in an orthotopic mouse model of sinonasal cancer. Western blot analysis revealed that both MDA8788 cell lines express epithelial markers, but do not express mesenchymal markers or the endocrine marker synaptophysin.

Conclusions—This is the first report of the establishment of stable human-derived SNUC cell lines. The lines were highly tumorigenic and maintain the histologic and molecular features of the original tumor. These cell lines should serve as useful tools for the future study of SNUC biology and the development and testing of novel therapies for this deadly disease.

Correspondence to: Michael E. Kupferman, M.D., Associate Professor, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler, Unit 1445, Houston, TX 77030-4009, Phone: (713) 794-1910, Fax: (713) 794-4662, mekupfer@mdanderson.org.

Disclosure of Potential Conflicts of Interest: The authors declare that they have no potential conflicts of interests.

Keywords

Sinonasal undifferentiated carcinoma; cell lines; morphology; epithelial-mesenchymal transition markers; tumorigenicity

INTRODUCTION

Sinonasal undifferentiated carcinoma (SNUC) is a rare, highly aggressive cancer that arises in the nasal cavity and paranasal sinuses. Initially described by Frierson, et al. in 1986 (1), this tumor is on the spectrum of neuroendocrine sinonasal malignancies, which includes esthesioneuroblastoma, neuroendocrine carcinoma, and small cell carcinoma. There is a male predominance [2-3:1], and there are no known etiologic factors. SNUC is typically negative for Epstein-Barr virus (2, 3). In general, SNUC presents as large tumors involving multiple sinonasal structures, often extends into the orbital or cranial cavity and can metastasize to the cervical lymph nodes, lungs, bones, brain, and liver (2, 4-6).

The treatment of SNUC includes aggressive multimodal therapy with radiotherapy and chemotherapy and, in some instances, surgery (4, 6-8). Despite aggressive management, the prognosis remains poor, and the median survival time from diagnosis is less than 18 months (2, 3).

To better understand the biological features of SNUC and help develop new therapeutic strategies for this disease, establishing a reliable model for laboratory-based analysis is essential. While other sinonasal malignancy models have been described, these are not relevant to the biological characteristics of SNUC (9, 10). In this report, we describe the establishment and characterization of the first human SNUC cell line, and present the molecular and phenotypic behavior of this unique system.

MATERIALS AND METHODS

Primary tumor

A 74-year-old woman was diagnosed and treated at The University of Texas MD Anderson Cancer Center (MDACC) for a T4N0M0 SNUC of the right maxillary sinus. She had received induction chemotherapy with four cycles of etoposide and carboplatin with a partial response prior to undergoing surgical resection of the residual tumor. Under an approved Institutional Review Board protocol, a portion of the resected specimen and matching normal tissue were collected.

Ultrastructural characterization of the SNUC specimen

Transmission electron microscopy was performed by the High Resolution Electron Microscopy Facility at MDACC. A sample was taken from the central portion of the solid tumor from the sinonasal cavity specimen immediately after surgical extirpation, and was preserved in a solution containing 3% glutaraldehyde, 2% formaldehyde, and 0.1 M cacodylate (pH 7.3). Ultrathin sections were cut with an LKB Ultracut microtome (Leica, Deerfield, IL, USA), stained with uranyl acetate and lead citrate in an LKB Ultrastainer, and examined with a JEM 1010 transmission electron microscope (JEOL, Peabody, MA) at an accelerating voltage of 80 kV. Digital images were obtained using the AMT imaging system (Advanced Microscopy Techniques Corp., Danvers, MA).

Establishing SNUC cell lines from the patient's tumor

The resected specimen was rinsed in phosphate-buffered saline (PBS) containing 500 units of penicillin and 500 µg of streptomycin and was then rinsed in PBS three times. The specimen was minced into 1- to 2-mm³ pieces and cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen Corporation, Carlsbad, CA) containing 10% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO), 25 units of penicillin and 25 µg of streptomycin. After 1 month, about 40 tumor colonies were harvested using 3MM Whatman paper soaked with 0.05% trypsin, 0.0076% EDTA 4Na solution in PBS. The colonies were then transferred to 24-well plates and designated as passage 0. Once the passage 0 cells became confluent, they were sequentially replated. Because they were sensitive to regular trypsin-EDTA solution, the cells were treated with TrypLE Express Stable (Invitrogen) when they were expanded. Cells were maintained in 10% FBS DMEM containing 0.1 mg/mL of Primocin (InvivoGen, San Diego, CA). Two populations originally from independent colonies were designated MDA8788-6 and MDA8788-7 based on their initial colony numbers. Both the MDA8788-6 and MDA8788-7 lines were free from mycoplasma and murine pathogens by the Infectious Microbe PCR Amplification Test (University of Missouri, Research Animal Diagnostic Laboratory, Columbia, MO).

Acquired cell lines and cell culture

Three established human head and neck squamous carcinoma cells lines were used: UMSCC33, OSC19, MDA1386LN, and an established cancer-associated fibroblast cell line. All cell lines were grown on tissue culture dishes in DMEM supplemented with 10% heat-inactivated FBS.

STR genotyping

The genomic DNA from the acquired cell lines and from the original fresh frozen tissue were extracted using the Gentra Puregene cell kit (Qiagen, Inc., Valencia, CA) following the manufacturer's instructions. Short tandem repeat (STR) genotyping was performed by the Characterized Cell Line Core Facility at MD Anderson.

Karyotyping

G-banding and spectral karyotyping (SKY) were performed by MD Anderson's Molecular Cytogenetics Facility by using the following procedures:

Chromosome preparation—Exponentially growing cells were exposed to colcemid (0.04 µg/mL) for 25 minutes at 37°C and hypotonic treatment (0.075 M KCl) for 20 minutes at room temperature. Cells were fixed in a methanol and acetic acid (3:1 by volume) mixture for 15 minutes and washed three times in the fixative. The slides were air dried and processed for G-banding and SKY.

G-banding—G-banding was performed by treating the slides in trypsin and staining with Giemsa stain using a routine laboratory procedure (11) to characterize the cytogenetic alterations. Slides were analyzed using an Eclipse E400 microscope (Nikon Inc., Melville, NY) and images of metaphases were captured using an Applied Spectral Imaging system equipped with camera and karyotyping software (Vista, CA). A minimum of 15-20 metaphases were karyotyped from each sample.

Spectral karyotyping (SKY)—SKY was performed according to the manufacturer's protocol using human SKY Paint probes (Applied Spectral Imaging). Images were captured using a Nikon 80i microscope equipped with SKY software (Applied Spectral Imaging). At least 15-20 metaphases were analyzed in detail.

Cell proliferation assay

MDA8788 cells were plated on a 96-well plate at a density of $1-2 \times 10^4$ /well. After 3, 24, 48, 72, 90, and 120 hours, the culture media were removed; 100 μ L of double distilled water was added; and the plates were frozen and thawed three times. A total of 100 μ L of Hoechst 33342 solution (20 μ M in 10 mM Tris HCl, 2 M NaCl, 1 mM EDTA, pH 7.4) (Invitrogen) was added and measured at 360-nm excitation and 460-nm emission. The proliferation data were analyzed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA).

Soft agar colony-formation assay

Ten thousand MDA8788 cells were suspended in 0.3% agarose (Lonza Walkersville, Inc., Walkersville, MD) in DMEM containing 20% FBS. This suspension was overlaid onto a solid layer of 0.6% agarose in a six-well plate. The cells were treated with fresh DMEM containing 20% FBS every other day. Three weeks later, the cells were fixed with methanol, stained with 0.02% crystal violet and photographed at x10 magnification.

Anoikis assay

For determination of anoikis resistance, 2×10^6 viable MDA8788 cells were cultured as previously described (12).

Migration and invasion assays

Migration and invasion assays were performed as previously described (13) using OSC19 cells as a positive control. Briefly, 4×10^4 cells were plated on cell culture insert wells or Matrigel-coated wells (BD Biosciences, San Jose, CA) in DMEM containing 10% FBS and the degree of migration was determined after 48 hours.

Protein analysis

The cells from all lines (MDA8788-6, MDA8788-7, MDA1368LN, OSC19, UMSCC33 and cancer-associated fibroblasts) were lysed in lysis buffer (50 mM HEPES, 150 mM NaCl, 10 mM EDTA, 10% glycerol, 1% Triton X-100, pH 7.5) with proteinase inhibitors (1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 1X Complete protease inhibitor cocktail) (Roche Holding, Inc., South San Francisco, CA). Organ homogenates in TNN buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40] were clarified by centrifugation (total lysate). Antibodies were obtained as follows: pan-keratin (clone 80; Thermo Fisher Scientific, Waltham, MA), cytokeratin 8 (N1N3; GeneTex, Inc., Irvin, CA), cytokeratin 19 (Ab-1, clone A53-B/A2.26; Thermo Fisher Scientific), vimentin (clone V9; DAKO, Carpinteria, CA), E-cadherin (clone 36/E-cadherin; BD Biosciences), N-cadherin (clone 32; BD Biosciences), synaptophysin (clone SVP-38; Millipore, Bellerica, MA) and actin, α -smooth muscle (clone 1A4; Sigma-Aldrich).

Immunohistochemical analysis

Immunohistochemistry was conducted as previously described (14), using Cytokeratin Cocktail (mixture of Clone AE1/AE3; DAKO, clone CAM 5.2; BD Biosciences, MNF116; DAKO and clone Zym 5.2; Invitrogen), anti-E-cadherin (clone HECD-1; Invitrogen), anti- α -smooth muscle (clone 1A4; Sigma-Aldrich) and anti-vimentin (clone V9; DAKO).

Animal care

Male nude mice (aged 6-8 weeks) were purchased from the Animal Production Area of the National Cancer Institute-Frederick Cancer Research and Development Center (Frederick, MD). The mice were maintained in a pathogen-free environment and fed irradiated mouse chow and autoclaved reverse osmosis-treated water at facilities in accordance with current

regulations and standards of the U.S. Department of Agriculture, U.S. Department of Health and Human Services, and the National Institutes of Health. The mice were used in accordance with MD Anderson's Animal Care and Use Guidelines, and all animal procedures were done in accordance with a protocol approved by the institution's Institutional Animal Care and Use Committee.

Subcutaneous flank model

A total of seven or eight mice per cell line underwent subcutaneous injection with 1×10^6 cells suspended in a volume of 200 μL of PBS directly into the right flank with a 1-mL tuberculin syringe (Hamilton Co., Reno, NV) and a 30-gauge hypodermic needle. The same number of the cells suspended in a volume of 100 μL of PBS with 100 μL of Matrigel Matrix Growth Factor Reduced (BD Bioscience) were also injected into the left flank of the same mice because Matrigel is known to enhance the tumorigenicity of a wide range of cancer cell lines *in vivo* (15). Injected mice were then examined twice weekly for tumor development. When present, tumors were measured using calipers in cephalad-to-caudad and left-to-right dimensions. Tumor volume was calculated as $V = AB^2 (\pi/6)$, where A is the longest dimension of the tumor and B is the dimension of the tumor perpendicular to A . When the longest dimension reached 15 mm, the animals were euthanized with carbon dioxide. At the time of death, the tumors and lungs were harvested and placed in 10% buffered formalin solution overnight for fixation. Hematoxylin and eosin (H&E) staining was used on histologic sections.

Orthotopic skull base model

We used the soft palate model that was established in our group (16). Briefly, 1×10^6 MDA8788-6 cells were suspended in a volume of 15 μL of PBS with 15 μL Matrigel and injected into the muscle of the soft palate. To monitor orthotopic tumor growth *in vivo*, mice were examined by magnetic resonance imaging (MRI) after 12 days of the injection in the Small Animal Imaging Facility at MDACC. Anesthesia was induced using 5% isoflurane in oxygen, maintained using 1–3% in oxygen, and monitored according to respiratory rate using respiratory bellows and a small animal physiological monitoring system (Small Animal Instruments Inc., Stony Brook, NY, USA). All MRIs were acquired using a 7 T Biospec small animal imaging system (Bruker BioSpin, Rheinstetten, Germany) and imaging gradients with an inside diameter (ID) of 116 mm. A linear volume resonator (72 mm ID) was used for excitation, and a custom electronically tuned and actively decoupled RF surface coil (13 mm ID) was used for signal detection. Scout images to verify animal positioning were followed by high-resolution sagittal T_2 -weighted RARE scans (TE/TR 60/3,000 ms, 20 mm $\times$ 15 mm field of view (FOV), 256 $\times$ 128 image matrix, 1 mm slices, RARE factor 8, 5 averages), geometrically matched axial T_1 -weighted spin echo (TE/TR 11.5/1,000 ms, 20 mm $\times$ 15 mm FOV, 256 $\times$ 128 image matrix, 1 mm slices) and T_2 -weighted RARE images (TE/TR 60/3,000 ms, RARE factor 8, 5 averages) of the paramedian dorsal skin.

Images were viewed using ParaVision software (Bruker BioSpin, Rheinstetten, Germany) and ImageJ analysis software (rsb.info.nih.gov/ij/). Measurements were taken after comparison of T_1 and T_2 images to confirm consistency of cutaneous microanatomic strata. All measurements were taken using ParaVision software on representative T_2 -weighted axial slices.

We euthanized mice with carbon dioxide when they became moribund. At the time of death, the full heads of mice were obtained, fixed in formalin solution for 48 hours, decalcified in 5% formic acid for 4 days and paraffin embedded. H&E staining was done on histologic

sections of the head to determine the extent of tumor growth and the degree of invasion into surrounding structures.

Statistical Analysis

The unpaired 2-tailed t test was used to compare the differences in mean tumor volume between 2 groups (with or without Matrigel for the tumor injection) with GraphPad Prism 5. *P* values < 0.05 were considered statistically significant.

RESULTS

Histopathologic and genetic characteristics

Pathological analysis of the original tumor was performed and compared to the established cell lines. H&E staining of the primary tumor from the patient's biopsy demonstrated small-to medium-sized polygonal cells that formed nests, sheets, ribbons and trabeculae (Figure 1A), characteristic of the classical SNUC morphology. (1) After the induction chemotherapy, the tumor had developed a slight squamoid appearance (Figure 1B). Electron microscopy indicated undifferentiated polygonal cells with sparse intracellular membrane structures, as well as ribosomes, neurosecretory granules and lipid-filled vacuoles (Figure 1C, left); higher magnification showed that microtubules were present along with rough endoplasmic reticulum, polyribosomes and membrane-bound, dense-core, neurosecretory granules (Figure 1C, right). The established cell lines grew as adherent and tightly packed monolayers with a polygonal shape and large nuclei (Figure 1D). The morphology was maintained across all cell passages. STR fingerprinting was performed to characterize the isogenic nature of the MDA8788 cell lines to the parent tumor. All DNA extracted from the original specimen and the two new lines had identical short tandem repeats (Supplementary Table). Comparison to the ATCC STR database and STR data from 49 cell lines in our laboratory revealed that MDA8788 is a unique cell line, distinct from all others in our collection.

Cytogenetic analysis

Cytogenetic analysis of the MDA8788 cells was performed by using G-banding and SKY analysis. G-banding analysis revealed that 12 clonal markers (m1-m12) (Figures 2A and S1) were shared by both cell lines. By combining G-banding and SKY analysis (Figure 2B), the following translocations were identified; m1 t (1:17), m2 t (1:22), m3 t (1:15), m4 t (2:12), m5 t (4:15), m6 t (3:6), m7 t (8:19), m8 t (9:10), m9 t (9:16), m10 t (13:13), m11 t (14, 14) and m12 t (18:19).

Phenotypic behavior of MDA8788 cell lines

We next assessed the replicative behavior of the established cell lines utilizing Hoechst 33342 fluorescence dye. The doubling time of both MDA8788 cell lines was found to be approximately 40 hours, which was slower than a median doubling time of 26.5 hours in head and neck squamous cancer cell lines (10). To examine the ability of the tumors to grow under anchorage-independent conditions, we performed soft agar assays on both cell lines. Neither cell line formed colonies after 3 weeks, whereas MDA1386LN cells formed large colonies (Figure 3A). To test whether the MDA8788 cells are resistant to anoikis (anchorage-dependent programmed cell death), the cells were grown in suspension culture at various time points. Within 72 hours, most of the MDA8788-6 cells died while the MDA8788-7 cells displayed a 30% viability (Figure 3B). These results suggested that, while the SNUC cell lines had behavior characteristics that were reminiscent of squamous cell carcinomas, the lack of growth in soft agar and the relative anoikis sensitivity suggested a more epithelial-like phenotype. To examine the migratory and invasive potential of the

SNUC cells, the MDA8788-6 cells were evaluated by *in vitro* transwell migration and invasion assays. MDA8788-6 did not migrate or invade, even after 48 hours, whereas OSC19 showed both invasion and migration (Figure S2).

Epithelial-mesenchymal transition and neuroendocrine markers in SNUC cells

As SNUC tumors display both epithelial and mesenchymal biological features, we next sought to examine whether the established SNUC cells express epithelial and mesenchymal markers by western blotting (Figure 4A). Both MDA8788 cells displayed high expression of pan-keratin, while the original tumor specimen had minimum expression compared to the SNUC cell lines, OSC19 (used as a positive control) and UMSCC33 (used as a representative of squamous cell carcinoma from the maxillary sinus). To specify the types of cytokeratin the SNUC cells were expressing, two antibodies recognizing cytokeratin 8 and 19 were used for Western blotting. Our SNUC tumor specimen and cell lines were positive for both cytokeratins.

The MDA8778 cell lines also expressed the epithelial markers E-cadherin and β -catenin, but not the mesenchymal markers N-cadherin, vimentin or α -smooth muscle actin (Figure 4A). The expression pattern of the EMT markers did not change during the course of cell culture (Figure S3). On the other hand, the SNUC tumor was positive for all the markers including the mesenchymal markers (Figure 4A). To determine the origin of these mesenchymal markers seen in Western blotting studies, we performed an immunohistochemical analysis of surgical specimen. Examination of H&E stained SNUC specimen revealed areas of epithelial tumor as well as non-tumor components including stroma (Figure S4A). The areas of tumor expressed epithelial markers (keratins and E-cadherin, Fig.S4B and S4C, respectively), but did not express mesenchymal markers. On the other hand, the non-tumor area expressed mesenchymal markers (α -SMA and vimentin, Figures S4D and S4E, respectively) but did not express epithelial markers. Because SNUC is a neuroendocrine tumor, we also studied the expression level of synaptophysin. Neither the original tumor nor the MDA8788 cell lines showed any synaptophysin staining (Figure 4B), which is consistent with the immunohistochemical profile performed on the original tumor (data not shown).

Tumorigenicity of MDA8788 cells in nude mice

To determine whether the SNUC cell lines were tumorigenic *in vivo*, viable cells were injected into the flanks of nude mice with or without Matrigel. Both MDA8788-6 and MDA8688-7 cells formed tumors (Figures 5A and S5A, respectively), while Matrigel substantially enhanced the tumor growth statistically significantly by day 39 in MDA8788-6 and day 28 in MDA8788-7 ($P < 0.005$) (Figures 5B, 5C, and 5D and Figures S5B and S5C, respectively). Histopathological examination of the tumors revealed minimal differences in morphological characteristics between tumors of mice injected with or without Matrigel (data not shown). As expected, the tumors grown from both MDA8788-6 and MDA8788-7 cells (Figures 5E and S5D, respectively) had a histopathologic appearance similar to that of the original surgical specimen (Figure 1B), although the tumors from the MDA8788-7 line had a slightly more squamoid appearance than that of the MDA8788-6 line. Metastases were not identified in any of the mice at necropsy (data not shown).

Orthotopic skull base model of MDA8788 cells

To examine whether the SNUC cells represent clinical features, we injected MDA8788-6 cells into the soft palate of mice. The implanted cells developed visible tumors in nude mice and tumor invasion into the brain was observed by a T1-weighted image (Figures 6A and 6B). Staining with H&E showed local invasion into muscle (Figure 6C), bone (Figure 6D), nerve (Figure 6E), blood vessels (Figure 6F) and lymphatic vessels (Figure 6G). The *in vivo* behavior accurately reflected the invasive nature of SNUC tumors in patients.

DISCUSSION

The aim of this study was to establish a reliable and phenotypically-accurate tumor model system for SNUC, and we were successful in establishing and characterizing two novel isogenic SNUC cell lines. Malignant sinonasal tumors are clinically challenging because of their rarity, their proximity to vital structures, and their histologic variety within a complex anatomic region. These tumors comprise fewer than 3.6% of all malignancies seen in the head and neck (17). Among them, SNUC is particularly rare and aggressive. It was first described by Frierson, et al. in 1986 (1), and fewer than 100 cases had been reported by 2005 (18). Despite multimodality therapy, including surgical resection, chemotherapy and radiotherapy, the prognosis for patients with SNUC is poor; the median survival is less than 18 months (2, 3) and the 5-year survival is less than 20% (19).

The development and evaluation of new therapeutic approaches for SNUC has been limited by a lack of available models. To better understand and overcome the poor outcomes of patients diagnosed with this disease, establishment of a tumor model of SNUC is essential. Currently, there are few cell lines derived from sinonasal tumors; most of them were isolated from squamous cell carcinomas (9, 10), and one was established from an intestinal-type sinonasal adenocarcinoma (20). No stable SNUC cell lines had been reported prior to the development and characterization of the cell lines reported here. These new cell lines are designated MDA8788-6 and MDA8788-7, and they were derived from a T4N0M0 SNUC of the right maxillary sinus of a 74-year-old female who was diagnosed and treated at our center. STR genotyping analysis revealed the isogenic nature of the two MDA8788 cell lines and the parent tumor. The morphologic features of the cells were stable throughout cell culture. These results indicate that our newly established cell lines are representative of the disease, making them useful for pre-clinical studies of the biology and treatment of SNUC.

An analysis by Gil, et al. showed that 30% of the SNUCs have an abnormal karyotype. In our study, 12 chromosomal translocations were identified in both MDA8788 cell lines. None of these translocations matched with previous cytogenetic studies of SNUCs (21, 22). It will be interesting to investigate the functional impact of the observed chromosomal translocations as studies in other tumor types have identified oncogenic activation of proto-oncogenes at chromosomal breakpoints. Further analysis of the observed cytogenetic abnormalities with mutational studies may yield potential molecular targets in this disease.

We found it interesting that, despite the highly aggressive nature of SNUC in patients, the SNUC cell lines showed a less malignant phenotype in tumor models. For example, the doubling time of the cells was relatively slow; they did not form colonies in soft agar; and they were relatively sensitive to detachment. They did not migrate or invade in *in vitro* assays. On the other hand, the SNUC cells were highly tumorigenic in the mice. To determine the tumorigenic potential of the MDA8788 cell lines, the cells were heterotransplanted into nude mice. The cells formed solid tumors histologically identical to the original surgical specimen, indicating that our SNUC cell lines can be used as reliable reagents for *in vivo* preclinical studies. These findings indicate that the microenvironment of the tumor may play an important role for the development of SNUCs. Moreover, *in vitro* experiments may be less revealing, *vis-à-vis* potential therapeutic targets and, thus, well-designed animal studies may be required in this unique disease. It is known that SNUC presents as large tumors involving multiple sinonasal structures, often extends into the orbital or cranial cavity and can metastasize to the cervical lymph nodes, lungs, bones, brain and liver (2, 4-6). To determine the reliability of our SNUC cell lines in replicating phenotype of SNUCs in patients, the cells were orthotopically implanted to mice. Histological examination showed that developed tumors could invade into the nasal cavity

and cranial cavity, indicating that these SNUC cell lines and the orthotopic model may work as powerful preclinical tools.

Immunoblotting assay revealed that MDA8788 cells were positive for pan-keratin, cytokeratin 8, and cytokeratin 19, which are positive in SNUC specimens at high rates (4, 8, 23-26). Other epithelial markers and mesenchymal markers were also tested. The SNUC cell lines were also found to express the epithelial markers E-cadherin and β -catenin, but they do not express the mesenchymal markers N-cadherin, vimentin or α -smooth muscle actin, indicating that the SNUC cell lines have epithelial characteristics and not mesenchymal features. Interestingly, our SNUC specimen expressed the epithelial markers at lower levels than the SNUC cell lines and was positive for the mesenchymal markers. This may be the result of contamination of non-tumor cells, such as cancer-associated fibroblasts. Neither the surgical specimen nor the SNUC cells expressed synaptophysin, despite this tumor's neuroendocrine classification. Some researchers have already reported that SNUCs can often be synaptophysin-negative consistent with our finding (4, 8, 23, 27).

In summary, this is the first report of establishing stable human-derived SNUC cell lines. The cell lines are highly tumorigenic and maintain the histologic and molecular features of the original tumor when grown in murine models. Therefore, these lines may serve as useful tools for future studies of SNUC tumor biology, as well as in the development and testing of novel therapies for this deadly disease.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. TJ Liu and Dr. Yoshitsugu Mitani for providing technical support, Samar Jasser and Terri Astin for administrative assistance, and Lizzie Hess for her important editing of the manuscript.

Grant Support: This work was supported by the Pittsburgh Foundation Study of Sinonasal Malignancies; Various Donors Sinus Cancer Research Fund; The University of Texas MD Anderson Cancer Center institutional start-up funds (179475 and 179495); a National Cancer Institute-Cancer Center Core Grant (NCI CA16672); NIH Grant K08-DE019185 (MEK); Joint American-College of Surgeons – Triological Society Clinical Scientist Development Award (MEK); Sheila Newar Cancer Research Fund (MEK)

REFERENCES

1. Frierson HF Jr, Mills SE, Fechner RE, Taxy JB, Levine PA. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. *Am J Surg Pathol*. 1986; 10:771–9. [PubMed: 2430477]
2. Cerilli LA, Holst VA, Brandwein MS, Stoler MH, Mills SE. Sinonasal undifferentiated carcinoma: immunohistochemical profile and lack of EBV association. *Am J Surg Pathol*. 2001; 25:156–63. [PubMed: 11176064]
3. Jeng YM, Sung MT, Fang CL, Huang HY, Mao TL, Cheng W, et al. Sinonasal undifferentiated carcinoma and nasopharyngeal-type undifferentiated carcinoma: two clinically, biologically, and histopathologically distinct entities. *Am J Surg Pathol*. 2002; 26:371–6. [PubMed: 11859210]
4. Ejaz A, Wenig BM. Sinonasal undifferentiated carcinoma: clinical and pathologic features and a discussion on classification, cellular differentiation, and differential diagnosis. *Adv Anat Pathol*. 2005; 12:134–43. [PubMed: 15900114]
5. Ghosh S, Weiss M, Streeter O, Sinha U, Commings D, Chen TC. Drop metastasis from sinonasal undifferentiated carcinoma: clinical implications. *Spine (Phila Pa 1976)*. 2001; 26:1486–91. [PubMed: 11458156]

6. Mendenhall WM, Mendenhall CM, Riggs CE Jr, Villaret DB, Mendenhall NP. Sinonasal undifferentiated carcinoma. *Am J Clin Oncol*. 2006; 29:27–31. [PubMed: 16462499]
7. Tanzler ED, Morris CG, Orlando CA, Werning JW, Mendenhall WM. Management of sinonasal undifferentiated carcinoma. *Head Neck*. 2008; 30:595–9. [PubMed: 18383526]
8. Smith SR, Som P, Fahmy A, Lawson W, Sacks S, Brandwein M. A clinicopathological study of sinonasal neuroendocrine carcinoma and sinonasal undifferentiated carcinoma. *Laryngoscope*. 2000; 110:1617–22. [PubMed: 11037813]
9. Liebertz DJ, Lechner MG, Masood R, Sinha UK, Han J, Puri RK, et al. Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1. *Head Neck Oncol*. 2010; 2:5. [PubMed: 20175927]
10. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, et al. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. *Head Neck*. 2007; 29:163–88. [PubMed: 17312569]
11. Pathak S. Chromosome banding techniques. *J Reprod Med*. 1976; 17:25–8. [PubMed: 59808]
12. Kupferman ME, Patel V, Sriuranpong V, Amornphimoltham P, Jasser SA, Mandal M, et al. Molecular analysis of anoikis resistance in oral cavity squamous cell carcinoma. *Oral Oncol*. 2007; 43:440–54. [PubMed: 16978912]
13. Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. *Oncogene*. 2010; 29:2047–59. [PubMed: 20101235]
14. Bell D, Roberts D, Karpowicz M, Hanna EY, Weber RS, El-Naggar AK. Clinical significance of Myb protein and downstream target genes in salivary adenoid cystic carcinoma. *Cancer Biology & Therapy*. 2011; 12:569–73. [PubMed: 21785271]
15. Mullen P. The use of Matrigel to facilitate the establishment of human cancer cell lines as xenografts. *Methods Mol Med*. 2004; 88:287–92. [PubMed: 14634240]
16. Gelbard A, Kupferman ME, Jasser SA, Chen W, El-Naggar AK, Myers JN, et al. An orthotopic murine model of sinonasal malignancy. *Clin Cancer Res*. 2008; 14:7348–57. [PubMed: 19010850]
17. Barnes L. Surgical Pathology of the Head and Neck. 2001; 1 [cited; 786p.]. Available from: <http://search.ebscohost.com/login.aspx?direct=true&db=nlebk&AN=57141&site=ehost-live>.
18. Frierson, HF. Sinonasal undifferentiated carcinoma. In: Leon Barnes, JWE.; Peter, Reichart; David, Sidransky, editors. Pathology and genetics of head and neck tumors (World Health Organization classification of tumors). IARC Press; Lyon: 2005. p. 19
19. Gallo O, Graziani P, Fini-Storchi O. Undifferentiated carcinoma of the nose and paranasal sinuses. An immunohistochemical and clinical study. *Ear Nose Throat J*. 1993; 72:588–90. 93–5. [PubMed: 8223288]
20. Perez-Escuredo J, Garcia Martinez J, Garcia-Inclan C, Vivanco B, Costales M, Alvarez Marcos C, et al. Establishment and genetic characterization of an immortal tumor cell line derived from intestinal-type sinonasal adenocarcinoma. *Cell Oncol (Dordr)*. 2011; 34:23–31. [PubMed: 21360264]
21. Gil Z, Orr-Urtreger A, Voskoboinik N, Trejo-Leider L, Spektor S, Shomrat R, et al. Cytogenetic analysis of sinonasal carcinomas. *Otolaryngol Head Neck Surg*. 2006; 134:654–60. [PubMed: 16564392]
22. Gil Z, Orr-Urtreger A, Voskoboinik N, Trejo-Leider L, Shomrat R, Fliss DM. Cytogenetic analysis of 101 skull base tumors. *Head Neck*. 2008; 30:567–81. [PubMed: 18098307]
23. Bellizzi AM, Bourne TD, Mills SE, Stelow EB. The cytologic features of sinonasal undifferentiated carcinoma and olfactory neuroblastoma. *Am J Clin Pathol*. 2008; 129:367–76. [PubMed: 18285258]
24. Bourne TD, Bellizzi AM, Stelow EB, Loy AH, Levine PA, Wick MR, et al. p63 Expression in olfactory neuroblastoma and other small cell tumors of the sinonasal tract. *Am J Clin Pathol*. 2008; 130:213–8. [PubMed: 18628089]
25. Franchi A, Moroni M, Massi D, Paglierani M, Santucci M. Sinonasal undifferentiated carcinoma, nasopharyngeal-type undifferentiated carcinoma, and keratinizing and nonkeratinizing squamous cell carcinoma express different cytokeratin patterns. *Am J Surg Pathol*. 2002; 26:1597–604. [PubMed: 12459626]

26. Wenig BM. Undifferentiated malignant neoplasms of the sinonasal tract. Arch Pathol Lab Med. 2009; 133:699–712. [PubMed: 19415944]
27. Cordes B, Williams MD, Tirado Y, Bell D, Rosenthal DI, Al-Dhahri SF, et al. Molecular and phenotypic analysis of poorly differentiated sinonasal neoplasms: an integrated approach for early diagnosis and classification. Hum Pathol. 2009; 40:283–92. [PubMed: 19150107]

\$watermark-text

\$watermark-text

\$watermark-text

Statement of Translational Relevance

SNUC is a rare, highly aggressive cancer that arises in the nasal cavity and paranasal sinuses. Treatment of SNUC includes aggressive multimodality therapy, including chemoradiotherapy and surgical resection when needed. Despite aggressive management, the prognosis remains poor, and the median survival time is less than 18 months. Due to the rarity of this disease, few studies on SNUC have been conducted, and most of these are focused upon improved diagnostic accuracy. To understand the biological characteristics of SNUC and to develop novel alternative treatments, it is essential to establish a reliable and phenotypically accurate tumor model system for SNUC. Here we report the establishment and characterization of two novel SNUC cell lines that are highly tumorigenic and maintain the histologic and molecular features of the original tumor. These cell lines may serve as useful tools for the future study of SNUC and in the development and testing of novel therapies for this deadly disease.

Figure 1. Histopathologic characteristics of the original SNUC and cell morphology of MDA8788-6 and -7 cells

(A) H&E staining of the primary tumor from biopsy shows typical features of SNUC, with small- to medium-sized polygonal cells that form nests, sheets, ribbons and trabeculae (original magnifications x40 (left) and x200 (right)). (B) After induction chemotherapy, H&E staining of the tumor revealed a more squamoid morphology (original magnifications x40 (left) and x200 (right)). (C) Electron microscopy images. *Left:* Neurosecretory granules, lipid-filled vacuoles and ribosomes are visible (scale bar, 200 μ m). *Right:* Greater magnification reveals rough endoplasmic reticulum and polyribosomes (scale bar, 500 nm). (D) Each cell line was photographed at both x40 (left) and x100 (right) magnification at passages 2 and 50. From early passage to late passage, both lines maintained a similar morphologic appearance with adherent tightly packed, polygonal-shaped cells with large nuclei growing as a monolayer.

Figure 2. Cytogenetic analysis of the MDA8788-6 cell line
 Representative G-banding (**A**) and SKY karyotyping (**B**) results for MDA8788-6 cells showing structural rearrangements.

Figure 3. Anchorage-dependent growth in MDA8788 cells

(A) Colony-formation assay was performed in 0.3% soft agar. No colonies were observed in the MDA8788 cell lines after 3-weeks of culture. The MDA1386LN cell line was used as a positive control and formed large colonies. (B) Anoikis assay in MDA8788 cells. A total of 2×10^6 trypsinized cells in 10-mL of culture media in a 15-mL tube were cultured with rotation. Cell viability was examined by staining with 0.2% Trypan blue. By 72 hours, most of the MDA8788-6 cells underwent apoptosis, whereas the MDA8788-7 line was slightly more resistant to anoikis.

Figure 4. Expression pattern of epithelial-mesenchymal transition and endocrine markers in SNUC cells

Expression pattern of various epithelial and mesenchymal markers was analyzed by Western blotting. **(A)** The original tumor and the two MDA8788 cell lines expressed epithelial markers (pan-keratin, cytokeratin 8, cytokeratin 19, E-cadherin, and β -catenin), but did not express mesenchymal markers (N-cadherin, vimentin, and α -SMA). Cell lines used for positive controls were OSC19 (for pan-keratin, cytokeratins 8 and 19, E- and N-cadherins, and β -catenin), MDA1386LN (for vimentin), and cancer-associated fibroblast (CAF) (for α -SMA). The arrow head shows the molecular weight corresponding to N-cadherin. **(B)** Synaptophysin expression was negative in the original tumor and both MDA8788 cell lines. Total brain lysate from a mouse was used as a positive control. UMSCC33 was used as a representative of sinonasal squamous cell carcinoma.

Figure 5. Heterotransplantation of MDA8788-6 cells into nude mice

Tumorigenicity was examined by injecting cells into the flanks of the mice. Each color in Figures 5A and 5B indicates identification number of the mice. **(A)** The cells injected into the flanks without Matrigel formed tumors in 66% of mice (4 of 6 mice). **(B)** By adding Matrigel, tumors grew larger and faster than the ones without adding Matrigel. Tumor formation was observed in 100% of animals. **(C)** Mean tumor sizes. **(D)** Appearance of a subcutaneous MDA8788-6 tumor in a nude mouse. The cells were injected into the right flank without Matrigel and into the left flank with Matrigel. **(E)**. The tumors from MDA8788-6 had a similar histopathologic appearance as that of the original surgical specimen (H&E staining; original magnifications x40 (top) and x200 (bottom)).

Figure 6. Orthotopic transplantation of MDA8788-6 cells into nude mice

(A) Sagittal MR imaging of a tumor from the human MDA8788-6 SNUC line that had been implanted in the soft palate of a mouse. *C*, cerebrum; *T*, tumor. (B) MR imaging of serial axial images 12 days after of the injection. (C-G) H&E staining shows several types of invasions. *T*, Tumor; *M*, muscle; *B*, bone; *N*, nerve; *RBC*, red blood cells, *V*, vessel (original magnification x200) (C) Muscle invasion. (D) Bone invasion. (E) Perineural invasion. (F) Vascular invasion. (G) Lymphovascular invasion.